Clinical Trial Update: Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on HN2302 assessing safety and preliminary efficacy in autoimmune diseases, including systemic lupus erythematosus and systemic sc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• HN2302

Snippet

Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Conditions: Autoimmune Disease, Systemic Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING